Tango Therapeutics (NASDAQ:TNGX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03), Zacks reports. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million during the quarter, compared to analysts' expectations of $7.84 million.
Tango Therapeutics Stock Down 8.2 %
Shares of Tango Therapeutics stock traded down $0.17 during trading hours on Monday, reaching $1.90. 1,285,840 shares of the stock traded hands, compared to its average volume of 771,501. The company has a 50 day moving average price of $2.83 and a 200 day moving average price of $5.23. Tango Therapeutics has a one year low of $1.81 and a one year high of $12.02. The firm has a market capitalization of $204.09 million, a price-to-earnings ratio of -1.61 and a beta of 0.80.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. B. Riley decreased their price target on Tango Therapeutics from $16.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, November 11th. Guggenheim decreased their target price on Tango Therapeutics from $18.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.33.
Get Our Latest Report on Tango Therapeutics
Insider Transactions at Tango Therapeutics
In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares of the company's stock, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 24,268 shares of company stock worth $72,561 in the last quarter. Company insiders own 6.30% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
